| Subgroup | Studies | Episodes | Risk Ratio (M-H, Fixed, 95% CI) (<1 favours monotherapy, >1 favours dual therapy) |
|---|---|---|---|
| Overall | 70 | 10429 | 0.97 [0.92, 1.01] |
| Same beta-lactam in both trial arms | 15 | 2761 | 1.11 [1.02, 1.21] |
| Different beta-lactam in each trial arm | 55 | 7668 | 0.92 [0.87, 0.96] |
| Children, same beta-lactam in both trial arms | 1 | 91 | 2.74 [1.08, 6.98] |
| Children, different beta-lactam in each trial arm | 12 | 1018 | 0.97 [0.83, 1.13] |
| Mixed or unknown age group, same beta-lactam | 3 | 985 | 1.01 [0.90, 1.14] |
| Mixed or unknown age group, different beta-lactam | 10 | 1803 | 0.92 [0.83, 1.03] |
| Adults, same beta-lactam | 11 | 1685 | 1.17 [1.04, 1.32] |
| Adults , different beta-lactam | 29 | 4160 | 0.90 [0.85, 0.96] |
| Haematological malignancies, same beta-lactam | 3 | 49 | 1.04 [0.90, 1.21] |
| Haematological malignancies, different beta-lactam | 24 | 3603 | 0.93 [0.87, 1.00] |
| Patients with severe neutropenia (ANC <100/mm3), same beta-lactam | 2 | 237 | 1.48 [1.12, 1.96] |
| Patients with severe neutropenia (ANC <100/mm3), different beta-lactam | 9 | 871 | 0.96 [0.84, 1.10] |
| Patients with bacteraemia, same beta-lactam | 6 | 395 | 1.05 [0.90, 1.23] |
| Patients with bacteraemia, different beta-lactam | 20 | 1149 | 0.86 [0.78, 0.95] |
From: Initial Treatment: guideline chapter six
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.